Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases

2007 ◽  
Vol 38 (10) ◽  
pp. 1489-1495 ◽  
Author(s):  
Nathalie Rioux-Leclercq ◽  
Patricia Fergelot ◽  
Salim Zerrouki ◽  
Emmanuelle Leray ◽  
Florence Jouan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Plasma Level ◽  
Prospective Study ◽  
Renal Cell ◽  
Tissue Expression ◽  
Vascular Endothelial ◽  
A Prospective Study ◽  
Endothelial Growth Factor

997: Glucocorticoids Down-Regulate Vascular Endothelial Growth Factor (VEGF) Production in Renal Cell Carcinoma Cells

2004 ◽  
Vol 171 (4S) ◽  
pp. 264-264
Author(s):  
Aki Iwai ◽  
Yasuhisa Fujii ◽  
Satoru Kawakami ◽  
Ryoji Takazawa ◽  
Yukio Kageyama ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

2017 ◽  
Vol 5 (2) ◽  
pp. 167-172 ◽  
Author(s):  
Fahredin Veselaj ◽  
Suzana Manxhuka-Kerliu ◽  
Arber Neziri ◽  
Labinot Shahini ◽  
Shefki Xharra ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cell ◽  
Prognostic Value ◽  
Clear Cell ◽  
Vascular Endothelial ◽  
Cell Renal Cell Carcinoma ◽  
Free Survival ◽  
Endothelial Growth Factor

BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.MATERIAL AND METHODS: Tumour blocks were taken from 40 patients with histopathology diagnosis of CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-histochemical staining for VEGF-A.RESULTS: The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (U’ = 720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific Survival   (r = -0.207, P = 0.713).CONCLUSIONS: VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for VEGF-A expression in all patients with advanced and metastatic CCRCC.

scholarly journals A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies

Cancer ◽  
2016 ◽  
Vol 122 (15) ◽  
pp. 2389-2398 ◽  
Author(s):  
Rana R. McKay ◽  
Guillermo De Velasco ◽  
Lillian Werner ◽  
Joaquim Bellmunt ◽  
Lauren Harshman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Phase 1 ◽  
Vascular Endothelial ◽  
Phase 1 Study ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document